Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
PROGRESS PHARMA from Vosselaar, company number BE0536258560, closed financial year 2025 with a result of € -5,479 after tax. For that financial year PROGRESS PHARMA recorded a gross margin of € -4,893 and equity of € 47,137. Compared with financial year 2024, the result moved from € -2,921 to € -5,479. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.
€ 47,137
▼ 49% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -5,479
▼ 88 % more loss than in 2024
Profit after tax over the fiscal year.
€ 18,108
▼ 71% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -14,363.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2,630
▲ 84% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -941 | € -1,173 | € -2,351 | € -4,893 | ▼ € 2,542 |
| Profit after taxes | € -1,402 | € -1,775 | € -2,921 | € -5,479 | ▼ € 2,558 |
| Equity | € 97,312 | € 95,537 | € 92,616 | € 47,137 | ▼ 49% |
| Total debts | € 536 | € 1,110 | € 1,432 | € 2,797 | ▲ 95% |
| Cash | € 66,022 | € 64,821 | € 62,222 | € 18,108 | ▼ 71% |
| Retained profit | € -402,688 | € -404,463 | € -407,384 | € -14,363 | ▲ € 393,021 |
| Balance sheet total | € 97,848 | € 96,647 | € 94,048 | € 49,934 | ▼ 47% |
Key figures of PROGRESS PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PROGRESS PHARMA?
What happened at PROGRESS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 5,479. Source: NBB ↗
- New establishment in Vosselaar. KBO
- Start of the company according to the CBE. KBO
In short
From € 1,402 loss in 2022 to € 5,479 loss in 2025.
Management
Behind PROGRESS PHARMA are Luc Lammens, SALVEGEN HEALTHCARE BV, R&S CONSULTING BV, SIMBIOSIS.LIFE BV and CONCORDE CONSULTING BV. It owns 100% of Etherna immunotherapies itself.
Directors
According to the 2025 annual accounts
SALVEGEN HEALTHCARE BV
Managing director · represented by Emilius VAN DONGEN
Director · represented by Marina COOLS
Director · represented by Dirk VAN BROEKHOVEN
Establishments
Establishment units
Physical locations of this company
Roekendreef 14
2350 Vosselaar
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0536.258.560
- VAT number
- BE 0536.258.560
- Registered office
- Roekendreef 14, 2350 Vosselaar
- Names & denominations
- PROGRESS PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 27 June 2013
- Peppol
- Active · Active since 4 Jun 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige zakelijke dienstverlening, neg